PODD

PODD SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Insulet Corporation Investors - Contact Kirby McInerney LLP by August 31, 2026

Insulet PODD Faces Securities Class Action Over Manufacturing Issues, Lead Plaintiff Deadline Near

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Insu...

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Insulet (PODD) is named in a securities-fraud class action alleging misleading disclosures about manufacturing controls during 2025–2026. The action follows two voluntary Pod corrections in March and May 2026 that coincided with stock declines, but the filing itself does not introduce new price-relevant information. Settlements or regulatory actions could influence PODD&#039;s risk and margins in the near term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kirby McInerney files securities class action against Insulet (PODD). Lead plaintiff deadline Aug 31, 2026.</li><li>Lawsuit alleges Insulet misled investors by failing to disclose manufacturing controls.</li><li>March 12 and May 26, 2026 corrections triggered prior share declines.</li><li>The release is a solicitation; no new price-relevant facts.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Insulet Corporation (PODD)</strong>: Subject of securities class action; litigation risk may affect sentiment and valuation.</li><li><strong>Kirby McInerney LLP (N/A)</strong>: Lead plaintiff law firm in the suit; not a public company but may amplify negative sentiment.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The article centers on a securities class action against PODD, highlighting litigation risk that could influence investor sentiment, potential settlements, and regulatory exposure, even if no new material facts about PODD are introduced.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Lead plaintiff deadline August 31, 2026 could drive near-term volatility.</li><li>March and May 2026 corrections previously pressured Insulet&#039;s shares.</li><li>Litigation risk may affect margins, regulatory scrutiny, or recall costs.</li><li>Absent new facts, price action hinges on settlement prospects and court rulings.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class Period: February 21, 2025 – May 26, 2026.</li><li>Lawsuit alleges misrepresentation of manufacturing controls and related safety risk.</li><li>March 12, 2026: voluntary Medical Device Correction for Omnipod 5 Pods announced.</li><li>May 26, 2026: voluntary correction for Omnipod 5, Omnipod Dash, Omnipod Eros announced.</li><li>Insulet stock declined 7% on March 12 (to $219.84) and 5% on May 26 (to $146.01).</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term PODD may experience volatility on litigation headlines; monitor for settlement news or court updates.</p>
  </section>
</section>


<article>
  <section>
    <h2>PODD Securities Fraud Lawsuit Filed on Behalf of Insulet Investors</h2>
    <p>NEW YORK, July 27, 2026 — Kirby McInerney LLP reminds Insulet Corporation investors, trading under the ticker PODD, of a pending securities fraud class action. The complaint targets alleged misleading statements related to manufacturing controls and safety, asserting that these omissions posed a heightened risk of regulatory violations or injury. The action is brought on behalf of those who purchased Insulet securities during the period February 21, 2025 through May 26, 2026, inclusive. If you suffered a loss in PODD during the Class Period, you may seek lead plaintiff status by <strong>August 31, 2026</strong>.</p>
  </section>

  <section>
    <h3>Lawsuit Background and Class Period</h3>
    <p>The lawsuit has been filed on behalf of investors who purchased securities during the period of <strong>February 21, 2025 through May 26, 2026, inclusive</strong> ("the <strong>Class Period</strong>"). The complaint alleges that throughout the Class Period, Insulet made public statements that were misleading for failure to disclose that: (i) Insulet’s manufacturing controls and procedures were defective and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.</p>
  </section>

  <section>
    <h3>Key Disclosures and Stock Price Reactions</h3>
    <p>On <strong>March 12, 2026</strong>, Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." On this news, Insulet's share price declined by <strong>$16.23 per share</strong>, or approximately <strong>7%</strong>, from <strong>$236.07</strong> per share on March 12, 2026 to close at <strong>$219.84</strong> on March 13, 2026.</p>
    <p>Then, on <strong>May 26, 2026</strong>, Insulet disclosed the "initiation" of another "voluntary Medical Device Correction," this time "for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery." On this news, the price of Insulet shares declined by <strong>$7.79 per share</strong>, or approximately <strong>5%</strong>, from <strong>$153.80</strong> per share on May 26, 2026 to close at <strong>$146.01</strong> on May 27, 2026.</p>
  </section>

  <section>
    <h3>What Investors Should Do</h3>
    <p>If you purchased or otherwise acquired Insulet securities, have information, or would like to learn more about this investigation, please contact <a href="#" rel="nofollow" target="_blank">Lauren Molinaro</a> of <a href="#" rel="nofollow" target="_blank">Kirby McInerney LLP</a> by email at <a href="#" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.</p>
    <p>If you suffered a loss on your Insulet investments, you have until <strong>August 31, 2026</strong> to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements <a href="#" rel="nofollow" target="_blank">here</a>.</p>
  </section>

  <section>
    <h3>Class Action Details and How to Learn More</h3>
    <p>Follow the link below for more information about the lawsuit:</p>
    <p style="text-align:center">[<a href="#" rel="nofollow" target="_blank">CONTACT THE FIRM IF YOU SUFFERED A LOSS</a>]</p>
  </section>

  <section>
    <h3>About the Lawsuit and Class Period Details</h3>
    <p><strong>What Is The Lawsuit About?</strong></p>
    <p>The lawsuit has been filed on behalf of investors who purchased securities during the period of <strong>February 21, 2025 through May 26, 2026</strong>, inclusive ("the Class Period"). The lawsuit alleges that throughout the Class Period, Insulet made public statements that were misleading for failure to disclose that: (i) Insulet’s manufacturing controls and procedures were defective and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.</p>
  </section>

  <section>
    <h3>Additional Disclosures and Market Response</h3>
    <p>On <strong>March 12, 2026</strong>, Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." On this news, Insulet's share price declined by <strong>$16.23 per share</strong>, or approximately <strong>7%</strong>, from <strong>$236.07</strong> per share on March 12, 2026 to close at <strong>$219.84</strong> on March 13, 2026.</p>
    <p>Then, on <strong>May 26, 2026</strong>, Insulet disclosed the "initiation" of another "voluntary Medical Device Correction," this time "for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery." On this news, the price of Insulet shares declined by <strong>$7.79 per share</strong>, or approximately <strong>5%</strong>, from <strong>$153.80</strong> per share on May 26, 2026 to close at <strong>$146.01</strong> on May 27, 2026.</p>
  </section>

  <section>
    <h3>Lead Plaintiff Eligibility and Process</h3>
    <p>If you purchased or otherwise acquired Insulet securities, have information, or would like to learn more about this investigation, please contact <a href="#" rel="nofollow" target="_blank">Lauren Molinaro</a> of <a href="#" rel="nofollow" target="_blank">Kirby McInerney LLP</a> by email at <a href="#" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.</p>
  </section>

  <section>
    <h3>Attorney Advertising and Firm Information</h3>
    <p><strong>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</strong></p>
    <p><a href="#" rel="nofollow" target="_blank">Kirby McInerney LLP</a> is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s <a href="#" rel="nofollow" target="_blank">website</a>.</p>
  </section>

  <section>
    <h3>Contacts</h3>
    <ul>
      <li>Kirby McInerney LLP</li>
      <li>Lauren Molinaro, Esq.</li>
      <li>212-699-1171</li>
      <li><a href="#" rel="nofollow" target="_blank">https://www.kmllp.com</a></li>
      <li><a href="#" rel="nofollow" target="_blank">investigations@kmllp.com</a></li>
    </ul>
  </section>
</article>

Insulet (PODD) is named in a securities-fraud class action alleging misleading disclosures about manufacturing controls during 2025–2026. The action follows two voluntary Pod corrections in March and May 2026 that coincided with stock declines, but the filing itself does not introduce new price-relevant information. Settlements or regulatory actions could influence PODD's risk and margins in the near term.

News insight

PODD SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Insulet Corporation Investors - Contact Kirby McInerney LLP by August 31, 2026

AI summary

Sentiment rationale

Key facts

Legal